PPARA and kidney disorder: Therefore, pemafibrate is potentially more effective in decreasing the triglyceride levels and inflammation than other existing PPARα agonists, thereby inhibiting dyslipidemia‐associated diseases, including cardiovascular and renal disorders (Hennuyer et al., 2016; Kawanishi et al., 2020).